The ‘smart pill’ market could be worth $3B by 2025 – meet the key players

January 5, 2018 Digital Health, Ingestibles, Medical Technology, Minimally Invasive, Pharmaceuticals, R&D

The “smart pill” market is expected to nearly quadruple in value to $3 billion by 2025, according to Grand View Research. Driving this growth is an increasing demand for minimally-invasive procedures, as well as better patient monitoring capabilities.

There are a number of players in the pharmaceutical and medtech arenas looking to stake a claim to the smart pill market. The companies are segmented into two groups – those developing capsules used for endoscopy and those creating connected, swallowable drug-tracking systems.

Medtronic

Medtronic‘s (NYSE:MDT) SmartPill ingestible capsule measures pressure, acidity, temperature and transit time as it passes through a person’s gastrointestinal tract. Using this data, the system assess GI function and can provide diagnostic information like gastric emptying time and pressure patterns, according to the medtech titan.

Medtronic touts its system as the only motility test that can give a complete transit profile of the GI tract.

The company’s sensor-based capsule takes the place of multiple tests, including gastric emptying scintigraphy, radio opaque markers and whole gut scintigraphy. Also, as upper and lower GI symptoms often overlap, the technology can help localize abnormalities to certain parts of the GI tract.

CapsoVision

This privately-held medical device developer has created miniaturized imaging tech, like its CapsoCam Plus small bowel capsule endoscope system.

CapsoVision‘s CapsoCam Plus won 510(k) clearance from the FDA in 2016. It was a third generation product for the California-based company, but the first to be commercialized within the U.S.

The technology is designed to give a 360-degree panoramic lateral image of the small bowel to help clinicians spot small bowel abnormalities. The system includes the capsule endoscope, a retrieval kit, the data access system and software.

By Sarah Faulkner | Drug Delivery Business News

Image Credit: Medtronic

READ MORE

About Peter Coffaro 491 Articles

A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.